News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novavax, Inc. (NVAX) Release: One Year Follow-Up From RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels Of Immune Response


5/12/2014 9:09:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GAITHERSBURG, Md., May 12, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein vaccine in 220 elderly adults (60 years of age and older, with a mean age of 68) that was initiated in October 2012. In the placebo-controlled trial, subjects received a single injection of either 60µg or 90µg of the RSV F-protein vaccine candidate, with or without aluminum phosphate as an adjuvant. - See more at: http://www.globenewswire.com/news-release/2014/05/12/635417/10081227/en/One-Year-Follow-Up-From-RSV-F-Protein-Vaccine-Candidate-Phase-1-Elderly-Trial-Demonstrates-Sustained-Levels-of-Immune-Response.html#sthash.BKdERmCs.dpuf

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES